MEDIMMUNE'S ABEGRIN HELPFUL IN TREATING SOLID TUMORS

MedImmune has reported that preclinical and clinical data showed that Abegrin may provide a three-pronged approach to treat solid tumors. Abegrin is a monoclonal antibody that targets the alpha-v beta-3 integrin, which is a protein expressed on the surface of newly forming blood vessels, certain tumor types.

According to the company, results from the preclinical studies indicated that its mechanism of anti-tumor action may involve both direct and indirect effects on a tumor's ability to grow or spread. Majority of Abegrin's antitumor activity is likely mediated through antibody-dependent cellular cytotoxicity, the company stated.